Cell-based therapies like CAR-T show promise but their benefit across all conditions, such as in multiple myeloma, is still under investigation.

“i mean i guess i would say the cell-based therapies or things like car-t or tyson like lucille or these sort of novel cell products they still have a lot of promise and they have definitely shown sort of great responses in some people but the real question will be are they are they so beneficial in every condition we're trying some of those cell brace therapies in multiple myeloma and a lot of people are having remissions but those remissions are fleeting and it looks like everyone is having relapse”